

# TRUMENBA<sup>®</sup>

non-live (recombinant)  
meningococcal group B vaccine

MenB-fHBP

10 years to 25 years

DIN 02468751



**SUPPLIED:**  
prefilled syringe;  
needle not supplied



**PREPARATION:**  
ready-to-use;  
**DO NOT DILUTE**



**ADMINISTRATION:**  
IM injection



**APPROPRIATE USE:**

- Not publicly funded in SK
- See QR code for recommendations for use.
- **Off-label Use:** may be considered for  $\geq 26$  years\*



CIG



**BEYOND-USE EXPIRY DATE/TIME:**

- Check date on label (expiry date)
- 2°C and 8°C: use vaccine until expiry date.



**HANDLING:**

- **SHAKE VIGOROUSLY** before administration to re-suspend.



**APPEARANCE:**

- Homogeneous white suspension
- NO particulate matter/discoloration



**DOSE:**

- 0.5 mL



**SERIES/SCHEDULE:**

- **PRIMARY SERIES:**
  - Dosing schedule may depend on the risk of exposure and individual susceptibility to meningococcal serogroup B disease. See QR code for details.
  - 2-dose: 0, 6 months or 3-dose: 0, 4 weeks, 3rd dose to be given  $\geq 4$  months after 2nd dose (and at least 6 months after dose one).
- **BOOSTER:** May be considered for individuals at continued risk of invasive meningococcal disease. See PM for details.

\* as per the CIG

REFERENCES:

- TRUMENBA<sup>®</sup> product monograph
- Canadian Immunization Guide: Meningococcal vaccines
- CATMAT Statement on Meningococcal Disease and the International Traveller

Financial contribution:



Public Health  
Agency of Canada

Agence de la santé  
publique du Canada

25 MAR 2024

©2024 medSask // Townes & Park Designs